Open Access

Tableau I.

ADC approuvés ou en phases cliniques avancées (III ou II pivotale).

ADC (cytotoxique) Isotype et Cible Indication, date d’approbation/Statut Ph clinique
gemtuzumab ozogamicine (CAL) IgG4 CD33 2000-2010/2017 AML

brentuximab védotine (AUR) IgG1 CD30 2011 ALCL et lymphoma de Hodgkin

trastuzumab emtansine (MAY) IgG1 HER2+ 2013 cancer du sein métastatique HER2+++

inotuzumab ozogamicine (CAL) IgG4 CD22 2017 ALL and CLL

polatuzumab védotine (AUR) IgG1 CD79b 2019 DLBCL

sacituzumab govitécan (IRI)* IgG1 TROP-2 BLA, TNBC métastatique

enfortumab védotine (AUR)* IgG1 Nectine 4 BLA, Piv. Ph 2 cancer urothéliale

trastuzumab déruxtécan (EXA)* IgG1 HER2/neu+ Ph 3 cancer du sein HER2+++ vs T-DM1

trastuzumab duocarmazine (DUO)* IgG1 HER2/neu+ Ph 3 cancer du sein HER2+++ vs T-DM1

mirvetuximab soravtansine (MAY)* IgG1 Folate R1 Ph 3 cancer de l’ovaire épithélial

belantamab mafodotine (AUR) IgG1afuc BCMA Piv. Ph2 myélome multiple

loncastuximab tésirine (PBD) IgG1 CD19 Piv. Ph2 DLBCL

depatuxizumab mafodotine (AUR) IgG1 EGFRvIII Ph 3 glioblastome (étude stoppée)

rovalpituzumab tésirine (PBD) IgG1 DLL3 Ph 3 cancer du poumon à petites cellules (étude stoppée)

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.